Kinetic assessment and therapeutic modulation of metabolic and inflammatory profiles in mice on a high-fat and cholesterol diet.
The kinetics of metabolic and inflammatory parameters associated with obesity were evaluated in a murine diet-induced obesity (DIO) model using a diet high in fat and cholesterol. Cellular infiltration and mediator production were assessed and shown to be therapeutically modulated by the PPARgamma agonist rosiglitazone. C57BL/6 mice were maintained on a 45% fat/ 0.12% cholesterol (HF/CH) or Chow diet for 3, 6, 16, or 27 weeks. Flow cytometry was employed to monitor peripheral blood monocytes and adipose tissue macrophages (ATM). Gene expression and protein analysis methods were used to evaluate mediator production from total epididymal fat (EF), stromal vascular fraction (SVF), and sorted SVF cells. To investigate therapeutic intervention, mice were fed a HF/CH diet for 12 weeks and then a diet formulated with rosiglitazone (5 mg/kg) for an additional 6 weeks. A HF/CH diet correlated with obesity and a dramatic proinflammatory state. Therapeutic intervention with rosiglitazone attenuated the HF/CH induced inflammation. In addition, a novel population was found that expressed the highest levels of the pro-inflammatory mediators CCL2 and IL-6.
Engstrom
Laura W
LW
Department of Inflammation, Schering-Plough Research Institute, Kenilworth, NJ 07033, USA.
Bober
Loretta
L
Chen
Shu-Cheng
SC
Fine
Jay S
JS
Li
Ying
Y
Stanton
Michaela C
MC
Kinsley
David
D
Cui
Long
L
Jackson
James V
JV
Rojas-Triana
Alberto
A
Lundell
Daniel
D
Laverty
Maureen
M
Gustafson
Eric L
EL
Jenh
Chung-Her
CH
Kowalski
Timothy J
TJ
Manfra
Denise J
DJ
Cell Metab. 2007 Aug;6(2):96-8
17681144
PLoS One. 2009 Jun 09;4(6):e5844
19513120
Immunol Lett. 2003 Oct 31;89(2-3):267-70
14556988
Am J Physiol Endocrinol Metab. 2008 Sep;295(3):E586-94
18577694
Cytotherapy. 2004;6(1):7-14
14985162
J Clin Invest. 2003 Dec;112(12):1821-30
14679177
Gastroenterology. 2007 May;132(6):2191-207
17498512
Diabetes. 2007 Jan;56(1):16-23
17192460
Am J Physiol Gastrointest Liver Physiol. 2007 Jun;292(6):G1671-82
17322064
Immunol Lett. 2007 Oct 15;112(2):61-7
17719095
Endocr J. 2010;57(1):39-50
19822999
Inflamm Res. 2010 May;59(5):399-405
19916070
Nature. 2006 Dec 14;444(7121):860-7
17167474
Circulation. 2008 Feb 12;117(6):806-15
18227385
J Nutr. 2009 Sep;139(9):1667-76
19587123
J Clin Invest. 2007 Jan;117(1):175-84
17200717
J Clin Invest. 2006 Dec;116(12):3220-8
17143331
J Leukoc Biol. 2009 Nov;86(5):1105-9
19605698
J Lipid Res. 2008 Sep;49(9):1894-903
18503031
Cell Physiol Biochem. 2004;14(4-6):311-24
15319535
Curr Opin Clin Nutr Metab Care. 2005 Jul;8(4):347-54
15930956
Nature. 2005 Oct 6;437(7060):906-10
16208376
J Clin Invest. 2007 Jan;117(1):195-205
17200719
Nutr Rev. 2002 Sep;60(9):289-93
12296456
Cytokine Growth Factor Rev. 2004 Feb;15(1):61-76
14746814
J Leukoc Biol. 2008 Oct;84(4):882-92
18579754
PPAR Res. 2007;2007:83593
17389771
J Immunol. 2005 Jul 1;175(1):342-9
15972667
Diabetes Res Clin Pract. 2008 Dec 15;82 Suppl 2:S118-21
19027978
Nature. 2007 Jun 28;447(7148):1116-20
17515919
J Clin Invest. 2006 Jun;116(6):1494-505
16691291
Diabetes. 2007 Dec;56(12):2910-8
17848624
Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11779-84
15280540
Eur J Pharmacol. 2008 Apr 14;584(1):118-24
18329014
J Biol Chem. 2008 Aug 15;283(33):22620-7
18541527
Exp Cell Res. 2006 Apr 1;312(6):727-36
16386732
J Biol Chem. 2007 Nov 30;282(48):35279-92
17916553
Circ Res. 2007 Mar 2;100(4):e47-57
17272806
Gastroenterology. 2007 May;132(6):2169-80
17498510
J Clin Invest. 2003 Dec;112(12):1796-808
14679176
Am J Physiol Endocrinol Metab. 2007 Sep;293(3):E656-65
17578888
J Clin Invest. 2006 Jan;116(1):115-24
16341265
Cell Immunol. 2009;258(2):138-46
19423085
J Cell Physiol. 2001 Oct;189(1):54-63
11573204